October 18, 2019
A Dova Pharmaceuticals Inc. investor filed a proposed class action Friday in Delaware federal court asserting the company has violated securities laws by not filing enough information about its proposed $915 million tie-up with biopharmaceutical company Swedish Orphan Biovitrum.